ReviewTherapeutic advances in gastroenterology2021
Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures.
Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Diagnostic Utility of Single Nucleotide Polymorphism Microarray in Evaluating Pancreaticobiliary Brushing Specimens in Conjunction with Conventional Cytology.The Journal of molecular diagnostics : JMD · 2026Article
- Fluoroscopy-guided, sheath-assisted biopsy for indeterminate intraductal biliary masses.Endoscopy · 2026Article
- Multimodal endoscopic diagnosis in biliary oncology: integrating EUS-guided tissue acquisition and cholangioscopy for personalized cancer care.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Endoscopic Retrograde Cholangiopancreatography (ERCP) Brush-Based Cytology Vs Biopsy: a Comparative Diagnostic Study.Maedica · 2025Article
- The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study.Hepatology communications · 2025Observational
- Morphologic and molecular diagnostic criteria of malignancies in biliary strictures.Histology and histopathology · 2025Review
- Genetic Uncertainties Fueling Cholangiocarcinoma Progression.Current genomics · 2025Review
- Review
- Fluorescence In Situ Hybridization in Primary Diagnosis of Biliary Strictures: A Single-Center Prospective Interventional Study.Biomedicines · 2023Article
- Histological assessment of new cholangioscopy-guided forceps in ERCP biliary stricture sampling: a blinded comparative study.Endoscopy international open · 2022Article
- Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review.Cancer management and research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cholangiocarcinoma have poor survival since the majority of patients are diagnosed at a stage precluding surgical resection, due to locally irresectable tumors and/or metastases. Optimization of diagnostic strategies, with a principal role for tissue diagnosis, is essential to detect cancers at an earlier stage amenable to curative treatment. Current barriers for a tissue diagnosis include both insufficient tissue sampling and a difficult cyto- or histopathological assessment. During endoscopic retrograde cholangiopancreatography, optimal brush sampling includes obtaining more than one brush within an individual patient to increase its diagnostic value. Currently, no significant increase of the diagnostic accuracy for the new cytology brush devices aiming to enhance the cellularity of brushings
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.